🇺🇸 FDA
Pipeline program

TAK-279 Placebo (same excipient as TAK-279), ZASOCITINIB

TAK-279-UC-2001

Phase 2 small_molecule active

Quick answer

TAK-279 Placebo (same excipient as TAK-279), ZASOCITINIB for Moderate to Severely Active Ulcerative Colitis is a Phase 2 program (small_molecule) at Takeda with 1 ClinicalTrials.gov record(s).

Program details

Company
Takeda
Indication
Moderate to Severely Active Ulcerative Colitis
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials